Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Anxiety Disorders

Ketamine for Anxiety Disorders

129 papers and 30 clinical trials exploring ketamine as a treatment for anxiety disorders.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

129 papers
Open Accessindividual

Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study

This observational study (n=45) followed people with treatment-resistant depression for up to 5 years and found that adjunctive intranasal esketamine was linked with sustained reductions in depression scores in those who stayed on treatment. No hypomania or mania was seen, and side effects were generally low.

Published
April 20, 2026
Journal
Therapeutic Advances in Psychopharmacology
Authors
Cuomo, A., McIntyre, R., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., Fagiolini, A.
Open Accessindividual

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

This cross-sectional survey (n=1,088) found that age significantly moderates the relationship between lifetime psychedelic use and mental health, with classic psychedelics such as psilocybin being associated with lower depression and anxiety in younger adults, but these benefits diminish with age and even reverse for anxiety in older participants.

Published
March 10, 2026
Journal
Research Square
Authors
Gregorio, G. D., Basset, S., Manmohan, H., Nixon, W. C., Pogaku, A., Zhou, J., Sanderson, D. J., Lengieza, M. L., Bocchio, M.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

This multicenter, randomised, placebo-controlled clinical trial (n=236) investigates the efficacy and safety of esketamine (ESK) (8x35mg) for smoking cessation in patients with lung cancer and major depressive disorder (MDD). Eight weekly intranasal ESK sessions significantly improved both self-reported (44.1%) and biologically verified (28.8%) smoking abstinence at 6-month follow-up, alongside reductions in depression, anxiety, nicotine dependence, and respiratory symptoms.

Published
August 1, 2025
Journal
Journal of Affective Disorders
Authors
Hong, C. J.
Open Accessmeta

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis

This meta-analysis of 17 trials found that control-group participants in psilocybin depression trials showed markedly smaller improvements (SMC ≈ 0.50) on the MADRS than control participants in SSRI (SMC ≈ 1.00) or esketamine (SMC ≈ 1.12) trials. The authors conclude this disparity may indicate that psilocybin’s antidepressant efficacy is overestimated relative to SSRIs and esketamine, possibly because of functional unblinding and expectancy effects.

Published
July 30, 2025
Journal
JAMA Network Open
Authors
Hieronymus, F., López, E., Sjögren, H. W., Lundberg, J.
Open Accessindividual

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program

In a naturalistic open‑label study of 185 adults with severe treatment‑resistant depression, twice‑weekly individually titrated oral esketamine for six weeks significantly reduced depressive symptoms (HDRS‑17 mean 21.2→15.8, p<0.001) with MCID 47.1%, response 26.8% and remission 15.6%, and a low dropout rate (7.6%). Treatment was generally well tolerated with frequent but manageable side effects and no significant urinary or cognitive adverse effects, suggesting oral esketamine is a safe, patient‑friendly option with effectiveness comparable to other administration routes.

Published
April 25, 2025
Journal
Journal of Psychopharmacology
Authors
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A., Spijker, J., Schoevers, R. A., Kamphuis, J.

Clinical Trials

30 trials
Not yet recruitingPhase I/II

Ketamine Plus Exposure Therapy For Post-Traumatic Stress Disorder (PTSD)– Open Label Pilot Study Targeting Anxiety

This open-label Phase I/II trial (n=12) will study the effects of oral ketamine (beginning at 35 mg/70 kg and increasing to 140 mg/70 kg) in combination with prolonged exposure therapy for the treatment of post-traumatic stress disorder (PTSD).

Started
July 31, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12625000722493p
Not yet recruitingPhase I

Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients (Keta-Care)

Open-label single-group early phase I feasibility study (n=100) of flexible-dose (5–50 mg) intranasal ketamine self-administration over 8 weeks for depression and anxiety in palliative cancer patients.

Started
November 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06665568
WithdrawnPhase I

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

This open-label trial (n=0; withdrawn) was designed to investigate the viability of ketamine-assisted psychotherapy in treating emotional distress related to cancer.

Started
October 31, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05344625
TerminatedPhase I

Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers

This open-label clinical trial (n=12) aims to assess the feasibility of ketamine-assisted psychotherapy (KAP) for adults with non-operable gastrointestinal (GI) cancers suffering from existential distress.

Started
October 13, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06001372
CompletedPhase IV

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion

This Phase IV interventional trial (n=60) aims to investigate the effectiveness of intraoperative ketamine in reducing postoperative depressive symptoms in patients undergoing lumbo-peritoneal shunt insertion.

Started
September 29, 2023
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06060210
RecruitingPhase NA

Ketamine Treatment Plans for Chronic Conditions

Observational cohort study (n=500) evaluating real-world home and clinic ketamine treatment plans for people with chronic conditions (pain, depressive and anxiety disorders) and the effect of adjunct therapies.

Started
January 1, 2023
Type
observational
Randomized
No
Registry ID
NCT06038409

Explore further

Search all Ketamine papers Search all Anxiety Disorders trials Full Ketamine profile Full Anxiety Disorders profile